ESC Congress 2017

26 - 30 August 2017, Barcelona - Spain

Session Details

Poster session 4: Acute coronary syndromes
Mon 28 Aug 08:30 - 12:30 Miscellaneous Poster Session Posters - Poster Area
Learning Objectives: Posters are on display from 08:30 – 12:30. Presenters will be by their poster during the coffee break from 10:00 and 11:00 for posters viewing time.

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
08:30P3634Left ventricular (LV) geometry in severe post-ischemic LV dysfunction: the effect of remote area extracellular matrix remodelingStefano PERLINI (Pavia, Italy)
08:30P3635Comparison of short-term and long-term mortality between patients with ST- and non ST-segment elevation myocardial infarction in three French population registries of myocardial infarction.Vanina BONGARD (Toulouse, France)
08:30P3636The predictive value of hyperuricemia for long-term mortality in patients with or without type 2 diabetes of acute myocardial infarction treated with interventionYa-Ling YANG (Taipei, Taiwan ROC)
08:30P3637Modification of GRACE score with genetic markers in patients with acute coronary syndromesVasily KASHTALAP (Kemerovo, Russian Federation)
08:30P3638The characteristics, treatment and outcomes of patients with acute myocardial infarction from 2012-2015 in Estonian Myocardial Infarction RegistryGudrun VELDRE (Tartu, Estonia)
08:30P36391-year risk stratification of patients with acute myocardial infarction according to the pegasus-timi 54 criteria.Nicola COSENTINO (Milan, Italy)
08:30P3640Direct comparison of clinical outcomes of acute myocardial infarction in patients with and without hypertrophic cardiomyopathy - a propensity score matched 15-Year nationwide population-based studyVictor Chien-Chia WU (Taoyuan City, Taiwan ROC)
08:30P3641Role of beta-blockers in a contemporaneous treatment era of patients with acute coronary syndrome: a propensity-score matching analysis from a tertiary single-center.Ana Teresa TIMOTEO (Lisboa, Portugal)
08:30P3642Use of optimal medical therapy in acute coronary syndrome patients with a previous history of cardiovascular diseaseNiels HOEDEMAKER (Amsterdam, Netherlands)
08:30P3643Cardiac rupture in current primary PCI era: a multicenter cohort study of tokyo CCU network databaseMikio KISHI (Tokyo, Japan)
08:30P3645Metabolomics by nuclear magnetic resonance identifies patients at high risk of death within two years after acute coronary syndrome.Rossella MARCUCCI (Florence, Italy)
08:30P3646Trends in frequency and prognosis of post myocardial infarction pericarditis: ACSIS 2000-2013Adi LADOR (Tel Aviv, Israel)
08:30P3647Predictive value of big endothelin-1 on cardiovascular events in patients with myocardial infarction younger than 35 years oldBingyang ZHOU (Beijing, China People's Republic of)
08:30P3648Detailed temporal patterns of high-sensitivity-cardiac troponin I and T during long-term follow-up after acute coronary syndromeVictor Joharran VAN DEN BERG (Rotterdam, Netherlands)
08:30P3649Impact of extra-cardiac diseased location on long-term prognosis in patients with acute coronary syndrome who underwent percutaneous coronary interventionTakuya NAKAHASHI (Kanazawa, Japan)
08:30P3650Trends in prevention after acute myocardial infarction in patients with reduced left ventricle ejection fraction in PolandMariusz GASIOR (Zabrze, Poland)
08:30P3652Effect of euthyroid sick syndrome on long-term clinical outcome in patients with preserved left ventricular function after acute myocardial infarctionByung-Hee HWANG (Seoul, Korea Republic of)
08:30P3653Evolution of renal function after acute coronary syndrome and prognostic impact of serial renal assessments in patients with normal-to-moderately reduced glomerular filtration rates: BIOMArCS studyMilos BRANKOVIC (Rotterdam, Netherlands)
08:30P3655Acute Coronary Syndrome: application of the GRACE Score and the creation of the new Laboratorial Risk ScoreJulio Gil GONCALVES PEREIRA (Viseu, Portugal)
08:30P3656Association between prescription rates of guideline-directed medications and short-term outcome among 68182 Japanese patients with acute myocardial infarction. Kazuhiro NAKAO (Suita, Japan)
08:30P3657The impact of age on mortality in females compared to males after acute myocardial infarction.Syed AHSAN (New York, United States of America)
08:30P3658Characteristics and prognosis of acute myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the new ESC criteriaGiuseppe CILIBERTI (Polverigi, Italy)
08:30P3659Early and 12-month mortality among the young woman and men with acute myocardial infarction (analysis from the PL-ACS registry)Agnieszka GORGON-KOMOR (Bielsko-Biala, Poland)
08:30P3660Impact of left atrial dilatation on the progression of ischemic mitral regurgitation and the occurrence of adverse cardiovascular events in patients with acute myocardial infarction in circumflex arteRamon MASEDA URIZA (Ciudad Real, Spain)
08:30P3661Effect of severe mental disease on distribution of CAG, PCI, CABG and valve surgery following MI, a nationwide register based studyRubina ATTAR (Aalborg, Denmark)
08:30P3662CRP predicts cap thickness in the culprit lesions of patients with metabolic syndrome and acute myocardial infarction. An Optical Coherence Study Andreas SYNETOS (Athens, Greece)
08:30P3663Influence of weather condition on the occurrence of unstable angina pectoris in japan (from the tokyo cardiovascular care unit network)Hiroki NIIKURA (Tokyo, Japan)
08:30P3665Independent laboratory predictors of the risk of recurrent cardiovascular events in patients undergoing unstable angina with conservative treatment strategyIrina LAZAREVA (Minsk, Belarus)
08:30P3666Abnormal coronary vasomotor reactivity is frequent and associated with altered outcomes in patients with symptoms compatible with myocardial ischemia at rest.Olivier VARENNE (Paris, France)
08:30P3667Evaluation of the diagnostic precision of a single determination of high sensitivity troponin in the screening of acute coronary syndrome in the emergency room.Paula FLUVIA (Girona, Spain)
08:30P3668Lesion characteristics and prognosis of heart attack without obstructive coronary artery diseaseAkira TARUYA (Wakayama, Japan)
08:30P3669Impaired cGMP and cAMP signaling in patients with coronary vasospasm: changes during acute crisesHasan IMAM (Adelaide, Australia)
08:30P3670Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved european label: insights from PEGASUS-TIMI 54Per JOHANSON (Molndal, Sweden)
08:30P3671Effectiveness of oral P2Y12 inhibition in men and women with cardiovascular disease: a meta-analysis and modelling studyKuan Ken LEE (Edinburgh, United Kingdom)
08:30P3672High-sensitivity troponin: the challenge of improving classification and prognostic stratification of NSTE-ACSGiovanni PERETTO (Milan, Italy)
08:30P3673Differences in mortality between patients referred to coronary angiography with stable angina or unstable anginaKristina FLADSETH (Tromso, Norway)
08:30P3674Using an outpatient protocol for exclusion of acute coronary syndrome from the emergency department:is it safe?Lucas TOJAL SIERRA (Vitoria, Spain)
08:30P3675Transcoronary gradients of heme oxygenase-1 and coronary spasmMasanobu ISHII (Kumamoto, Japan)
08:30P3676 Prognosis of an invasive approach to unstable anginaLuis PUGA (S. Mamede De Infesta, Portugal)
08:30P3677Prognostic implication of gender difference in patients with coronary spasmKoichi KAIKITA (Kumamoto, Japan)
08:30P3678Evaluation of communication polymorphic variant CYP2C19 * 2 gene with resistance to clopidogrel in patients with unstable anginaIrina LAZAREVA (Minsk, Belarus)
08:30P3679A paradox of under-treatment of acute coronary syndrome patients with low baseline LDL-C <1.8mmol/LBryan Ping Yen YAN (Hong Kong, Hong Kong SAR People's Republic of China)
08:30P3680Treatment administrated to patients with myocardial infarction with non-obstructive coronary arteries in the real world and its impact on prognosis.Barbara IZQUIERDO (Madrid, Spain)
08:30P3681How to bridge residual distance to target LDL-C in acute coronary syndrome after initial statin therapy?Bryan Ping Yen YAN (Hong Kong, Hong Kong SAR People's Republic of China)
08:30P3682Early oral betablocker utilization reduces in-hospital mortality in patients submitted to primary percutaneous coronary intervention: a real-world analysis.Talia DALCOQUIO (Sao Paulo, Brazil)
08:30P3683Previous beta-blocker therapy on admission for acute coronary syndrome is associated with decreased intra-hospital mortality and major cardiovascular events in patients without heart failureCharbel ABI KHALIL (Doha, Qatar)
08:30P3684Early initiation of oral beta-blocker improves long-term survival in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention.Zhehao DAI (Tokyo, Japan)
08:30P3685Management of aspirin intolerance in patients undergoing percutaneous coronary intervention: the role of mono anti platelet therapy. A retrospective, multicenter, study.Matteo BIANCO (Orbassano, Italy)
08:30P3686Statin therapy improves glycemic control in diabetic patients admitted with acute coronary syndromes.Aline GEHLEN FERRARI (Sao Paulo, Brazil)
08:30P3687Clinical presentation and cardiovascular outcomes of patients with coronary artery ectasiaJose Antonio CORNEJO GUERRA (Mexico, Mexico)
08:30P3688Impact of insulin therapy on thienopyridine- and ticagrelor- mediated platelet inhibition in patients with an acute coronary syndromeLeslie Marisol LUGO GAVIDIA (Queretaro, Mexico)
08:30P3689Levels of platelet micro-RNA-223, microRNA-150 and microRNA-21 in patients with coronary artery disease during dual anti platelet therapy and after cessation of P2Y12-inhibitor therapyBernhard JAEGER (Vienna, Austria)
08:30P3690Impact of high on-treatment platelet reactivity on 1-year clinical outcome in elderly patients with NSTE-ACS undergoing percutaneous coronary intervention- insights from the GEPRESS study.Roberta DE ROSA (Napoli, Italy)
08:30P3691Predictors of newer P2Y12 inhibitors prescription at discharge in a contemporary cohort of patients with acute coronary syndromeMiriam GOMEZ MOLINA (El Palmar, Spain)
08:30P3692Underuse of prasugrel and ticagrelor in patients with chronic kidney disease despite achieving a more effective platelet inhibition than clopidogrelLeslie Marisol LUGO GAVIDIA (Queretaro, Mexico)
08:30P3693Thrombolytic therapy in acute myocardial infarction after previous revascularization; 29-year experience of the POP studyPredrag MITROVIC (Beograd, Serbia)
08:30P3694Multicenter research of bleeding risk between low dose prasugrel and standard dose clopidogrel in patients with coronary artery disease undergoing percutaneous coronary interventionSatoshi TOKIMASA (Chiba, Japan)
08:30P3695Pharmacokinetic profiles of orodispersible ticagrelor tablets in healthy Western and Japanese subjects.Eva BLYCHERT (Gothenburg, Sweden)
08:30P3696No differences in circulating progenitor endothelial cell levels among patients treated with ticagrelor as compared to clopidogrel during acute coronary syndromesJose Carlos MORENO SAMOS (Salamanca, Spain)
08:30P3697Prognostic role of non-ST resolution and glycoprotein IIbIIIa inhibitors use in STEMI patients treated with primary PCI Stefano CORNARA (Pavia, Italy)
08:30P3698Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practiceYan YAN (Beijing, China People's Republic of)
08:30P3699Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: a nationwide long-term registry analysis from 2009 to 2014Safoura SHEIKH REZAEI (Vienna, Austria)
08:30P3700Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary PCI in acute myocardial infarction of anterior locationSara BLASCO (Cadiz, Spain)
08:30P3701Health implications of regional differences in the implementation of new treatments for myocardial infarction: the case of ticagrelor in SwedenKasper Munk JOHANNESEN (Arsta, Sweden)
08:30P3702Risk factors and possible mechanisms of high on treatment platelet reactivity with clopidogrel therapy in Chinese patients with CHDJian CAO (Beijing, China People's Republic of)
08:30P3704Open-labeled randomised controlled study of double dose clopidogrel versus ticagrelor in stable coronary artery disease (CAD) patients with clopidogrel resistance.Hamat Hamdi CHE HASSAN (Kuala Lumpur, Malaysia)
08:30P3705Pre-hospital routine oxygen supplement may do harm: insight from tokyo CCU network databaseMikio KISHI (Tokyo, Japan)
08:30P3706Prognosis value of new ESC LVEF classification in acute coronary syndrome with and without heart failureAlvaro MARTINEZ (Santiago De Compostela, Spain)